ATE406881T1 - Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung - Google Patents

Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung

Info

Publication number
ATE406881T1
ATE406881T1 AT02733811T AT02733811T ATE406881T1 AT E406881 T1 ATE406881 T1 AT E406881T1 AT 02733811 T AT02733811 T AT 02733811T AT 02733811 T AT02733811 T AT 02733811T AT E406881 T1 ATE406881 T1 AT E406881T1
Authority
AT
Austria
Prior art keywords
alpha
beta unsaturated
radiation
toxicity
arylsulphones
Prior art date
Application number
AT02733811T
Other languages
English (en)
Inventor
Premkumar Reddy
Ramana Reddy
Stephen Cosenza
Lawrence Helson
Original Assignee
Univ Temple
Onconova Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Onconova Therapeutics Inc filed Critical Univ Temple
Application granted granted Critical
Publication of ATE406881T1 publication Critical patent/ATE406881T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02733811T 2001-02-28 2002-02-28 Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung ATE406881T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27199001P 2001-02-28 2001-02-28

Publications (1)

Publication Number Publication Date
ATE406881T1 true ATE406881T1 (de) 2008-09-15

Family

ID=23037934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02733811T ATE406881T1 (de) 2001-02-28 2002-02-28 Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung

Country Status (10)

Country Link
US (1) US6667346B2 (de)
EP (1) EP1370253B8 (de)
JP (1) JP4302986B2 (de)
KR (1) KR100850331B1 (de)
AT (1) ATE406881T1 (de)
AU (1) AU2002305942B2 (de)
CA (1) CA2439288C (de)
DE (1) DE60228692D1 (de)
IL (2) IL157541A0 (de)
WO (1) WO2002069892A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE461915T1 (de) 2000-10-05 2010-04-15 Univ Temple Substituierte (e)-styrylbenzylsulfone zur behandlung proliferativer erkrankungen
CA2477232C (en) * 2002-02-28 2011-07-19 Temple University - Of The Commonwealth System Of Higher Education Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
CA2477236C (en) * 2002-02-28 2013-08-13 Temple University - Of The Commonwealth System Of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
WO2005046599A2 (en) * 2003-11-14 2005-05-26 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
CA2546445A1 (en) * 2003-11-26 2005-06-16 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
ES2609084T3 (es) * 2004-03-16 2017-04-18 Temple University - Of The Commonwealth System Of Higher Education Derivados de fenoxi y feniltio sustituidos para tratar trastornos proliferativos
US8058313B2 (en) 2004-06-24 2011-11-15 Temple University—Of the Commonwealth System of Higher Education Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof
US8063109B2 (en) * 2004-07-19 2011-11-22 Onconova Therapeutics, Inc. Formulations for parenteral administration of (e)-2, 6-dialkoxystyryl 4-substituted benzylsulfones
US7537572B2 (en) 2004-10-22 2009-05-26 General Patent, Llc Treatment or pre-treatment for radiation/chemical exposure
KR101427105B1 (ko) * 2005-01-05 2014-08-07 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 약-내성 증식성 질병의 치료
CA2599169C (en) * 2005-02-25 2013-10-22 Temple University - Of The Commonwealth System Of Higher Education Synthesis of (e)-alpha, beta unsaturated sulfides, sulfones, sulfoxides and sulfonamides
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2007016201A2 (en) 2005-07-29 2007-02-08 Onconova Therapeutics, Inc. FORMULATION OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
EP1864692A1 (de) * 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
JP2007302640A (ja) * 2006-05-15 2007-11-22 Natl Inst Of Radiological Sciences 抗放射線被ばく障害剤
WO2008105808A2 (en) * 2006-07-28 2008-09-04 Onconova Therapeutics, Inc. FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
JP5278968B2 (ja) 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
US8273787B2 (en) * 2006-09-15 2012-09-25 Onconova Therapeutics, Inc Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
CA2671426C (en) * 2006-12-13 2015-05-26 Temple University - Of The Commonwealth System Of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues useful in the treatment of cancer and other proliferative disorders
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP2012504645A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
WO2010075026A2 (en) * 2008-12-16 2010-07-01 Onconova Therapeutics Inc Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human
ES2561216T3 (es) 2009-05-13 2016-02-25 The University Of North Carolina At Chapel Hill Inhibidores de cinasas dependientes de ciclina y procedimientos de uso
CA2792883A1 (en) * 2010-03-24 2011-09-29 Onconova Therapeutics, Inc. Compositions and methods for prevention and treatment of wounds
HRP20150918T1 (hr) * 2010-03-26 2016-01-29 Onconova Therapeutics, Inc Poboljšana stabilna vodena formulacija (e)-4-karboksistiril-4-klorobenzil sulfona
GB201010359D0 (en) 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
EP2640394A4 (de) 2010-11-17 2015-02-25 Univ North Carolina Schutz von nierengewebe vor ischämie durch die hemmung der proleverativen kinasen cdk4 und cdk6
JP6348904B2 (ja) 2012-09-20 2018-06-27 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 置換アルキルジアリール誘導体、その製造方法及び使用
CN107417691B (zh) 2013-03-15 2020-06-26 G1治疗公司 高效的抗赘生剂和抗增生剂
CN105407889B (zh) 2013-03-15 2018-06-01 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
CN104230770B (zh) * 2013-06-17 2017-11-21 华夏生生药业(北京)有限公司 苯乙烯基砜类化合物、其制备方法以及其作为神经保护剂的应用
WO2015101678A2 (en) * 2014-01-06 2015-07-09 Hackensack University Medical Center Method for treating skin cancer using radiation therapy
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2017023912A1 (en) 2015-08-03 2017-02-09 Temple University - Of The Commonwealth System Of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
CN106432011B (zh) * 2016-09-18 2018-11-02 中国医学科学院放射医学研究所 一类具有辐射防护作用的新化合物、其制备方法及其药物应用
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
CN114072380B (zh) * 2019-07-18 2024-03-15 华夏生生药业(北京)有限公司 氨基甲酸酯取代的苯乙烯基砜类化合物及其制备方法和用途
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1027330B1 (de) * 1997-10-03 2004-12-08 Temple University of the Commonwealth System of Higher Education Styrolsulfone als antikrebsmittel
US6201154B1 (en) * 1999-03-31 2001-03-13 Temple University-Of The Commonwealth Of Higher Education Z-styryl sulfone anticancer agents
AU3381399A (en) * 1999-04-02 2000-10-23 Temple University - Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
ATE298234T1 (de) * 1999-04-02 2005-07-15 Univ Temple (e)-styrylsulfone als krebsbestreitende mittel
AU780844B2 (en) * 1999-10-12 2005-04-21 Temple University-Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
AU2001251391A1 (en) * 2000-04-06 2001-10-23 Acorda Therapeutics, Inc. Compositions and methods for promoting neural regeneration
US6486210B2 (en) 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
DK1379508T3 (da) * 2001-02-28 2011-01-03 Univ Temple N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf

Also Published As

Publication number Publication date
KR100850331B1 (ko) 2008-08-04
JP4302986B2 (ja) 2009-07-29
EP1370253A4 (de) 2005-08-17
EP1370253B8 (de) 2008-11-26
DE60228692D1 (de) 2008-10-16
WO2002069892A3 (en) 2002-11-07
WO2002069892A2 (en) 2002-09-12
US20030060505A1 (en) 2003-03-27
US6667346B2 (en) 2003-12-23
CA2439288A1 (en) 2002-09-12
IL157541A0 (en) 2004-03-28
KR20030086596A (ko) 2003-11-10
JP2004525908A (ja) 2004-08-26
EP1370253A2 (de) 2003-12-17
AU2002305942B2 (en) 2006-10-26
CA2439288C (en) 2011-08-09
EP1370253B1 (de) 2008-09-03
IL157541A (en) 2010-05-31

Similar Documents

Publication Publication Date Title
ATE406881T1 (de) Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung
WO2005044181A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
Schuster et al. Side effects in cold plasma treatment of advanced oral cancer—Clinical data and biological interpretation
EA200000087A1 (ru) Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
WO2005065074A3 (en) Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
UY27186A1 (es) Formulación farmacéutica
Miller et al. Metformin exhibits radiation countermeasures efficacy when used alone or in combination with sulfhydryl containing drugs
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
JP2008519047A5 (de)
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
MXPA03003354A (es) Dispositivos medicos revestidos para el tratamiento de una enfermedad vascular.
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
BRPI0418157A (pt) terapêutica de tumores alogênicos
Anné et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
Grdina et al. Relationships between cytoprotection and mutation prevention by WR-1065
Rong et al. Advances in mitochondrial dysfunction in radiation tissue injury
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
DE60044092D1 (de) Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika
PE20011028A1 (es) Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino
Blakley et al. Differences in Ototoxicity across Species.
BR0208860A (pt) Uso de um derivado de dextrano catiÈnico, método para a proteção de um indivìduo contra o dano em órgãos com limitação de dose, e, método para a proteção de um indivìduo contra dano renal
ATE442188T1 (de) Bestrahlungseinrichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties